CCC publication: Characterization of cytokine release syndrome (CRS) following treatment with tebentafusp in patients (pts) with previously treated (2L+) metastatic uveal melanoma (mUM)

Citation: Journal of Clinical Oncology. 2021, 39(15)
Author: Carvajal R.D.; Sato T.; Butler M.O.; Sacco J.J.; Shoushtari A.N.; Hassel J.C.; Ikeguchi A.; Hernandez-Aya L.F.; Rioth M.; Hamid O.; Piulats J.M.; Luke J.J.; Johnson D.B.; Leyvraz S.; Espinosa E.; Collins L.; McCully M.L.; Lockwood S.; Abdullah S.E.; Nathan P.